LMAT vs. MDXG, CSII, CRY, SIBN, OFIX, STVN, INSP, MMSI, HAE, and AXNX
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include MiMedx Group (MDXG), Cardiovascular Systems (CSII), CryoLife (CRY), SI-BONE (SIBN), Orthofix Medical (OFIX), Stevanato Group (STVN), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), Haemonetics (HAE), and Axonics (AXNX). These companies are all part of the "medical" sector.
LeMaitre Vascular (NASDAQ:LMAT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
LeMaitre Vascular has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.
LeMaitre Vascular received 469 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.27% of users gave MiMedx Group an outperform vote while only 70.94% of users gave LeMaitre Vascular an outperform vote.
MiMedx Group has a net margin of 18.63% compared to LeMaitre Vascular's net margin of 16.99%. MiMedx Group's return on equity of 39.42% beat LeMaitre Vascular's return on equity.
In the previous week, LeMaitre Vascular had 4 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for LeMaitre Vascular and 3 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.08 beat LeMaitre Vascular's score of 0.87 indicating that MiMedx Group is being referred to more favorably in the news media.
LeMaitre Vascular currently has a consensus price target of $77.57, suggesting a potential downside of 1.66%. MiMedx Group has a consensus price target of $12.25, suggesting a potential upside of 71.33%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than LeMaitre Vascular.
84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 10.8% of LeMaitre Vascular shares are held by insiders. Comparatively, 1.3% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
MiMedx Group has higher revenue and earnings than LeMaitre Vascular. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
Summary
MiMedx Group beats LeMaitre Vascular on 10 of the 19 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
